26 / 33
Corral J. et al, ELCC 2017 abstract 93PD;
SS Ramalingam, ESMO 2017
LUX-Lung 7 (LL7):
patients treated with 3
rd
generation TKI
3 year OS rates afatinib followed by 3rd-generation TKI ≥90%
FLAURA:
Osimertinib vs SoC
FINAL IMPACT ON OS CAN BE BETTER THAN HISTORICAL